About Diopsys
Diopsys is a company based in Montville (United States) founded in 2002 was acquired by LumiThera in November 2021. Diopsys has raised $1.05 million across 1 funding round from investors including LumiThera. The company has 31 employees as of December 31, 2021. Diopsys offers products and services including NOVA Vision Testing System, VEP, and ERG. Diopsys operates in a competitive market with competitors including Sensimed, i-Optics, Azul Optics, Oxymap and Bioptigen, among others.
- Headquarter Montville, United States
- Employees 31 as on 31 Dec, 2021
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Diopsys, Inc.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Diopsys
Diopsys offers a comprehensive portfolio of products and services, including NOVA Vision Testing System, VEP, and ERG.
System for advanced vision testing and diagnostics in healthcare settings.
Technology for visual evoked potential testing in select countries.
Electroretinography device for eye function assessment outside the US.
People of Diopsys
Unlock access to complete
Funding Insights of Diopsys
Diopsys has successfully raised a total of $1.05M through 1 strategic funding round. The most recent funding activity was a Seed round of $1.05 million completed in October 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Diopsys
Diopsys has secured backing from 1 investor. Prominent investors backing the company include LumiThera.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Photobiomodulation treatments for ocular diseases are developed.
|
Locked | Locked | Locked |
Investor details for Diopsys
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Diopsys
Investment portfolio details for Diopsys
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Diopsys
Detailed financials for Diopsys
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Diopsys Comparisons
Peer comparison for Diopsys
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Diopsys
Diopsys operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Sensimed, i-Optics, Azul Optics, Oxymap and Bioptigen, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
A contact lens-based platform for glaucoma monitoring is offered.
|
|
| Locked | Locked | Locked |
i-Optics specializes in providing advanced retina and cornea imaging systems for medical professionals.
|
|
| Locked | Locked | Locked |
Device for assessing the eye health against damaging light
|
|
| Locked | Locked | Locked |
Retinal Imaging technology to assess retinal oxygen saturation and vessel width
|
|
| Locked | Locked | Locked |
Spectral domain OCT devices for ophthalmic imaging are developed.
|
|
| Locked | Locked | Locked |
Portable technologies for multifocal eye corrections before surgeries are developed.
|
Detailed competitors of Diopsys
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Diopsys
Complete news archive for Diopsys
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Diopsys
Diopsys was founded in 2002 and raised its 1st funding round 17 years after it was founded.
Diopsys is headquartered in Montville, United States. It is registered at Montville, New Jersey, United States.
Diopsys is a funded company, having raised a total of $1.05M across 1 funding round to date.
As of Dec 31, 2021, the latest employee count at Diopsys is 31.
Diopsys is a provider of non-invasive office-based visual electrophysiology medical devices that help ophthalmologists and optometrists analyze the entire visual pathway for visual and neuro-visual disorders. The company provides both Visual Evoked Potential (VEP) and Electroretinography (ERG) vision testing technology. Diopsys, Inc.s medical devices include the Diopsys NOVA and Diopsys ARGOS ERG and VEP Vision Testing System product series and the Enfant Pediatric VEP Vision Testing System.
Diopsys's top competitors include 2EyesVision, Sensimed and Azul Optics.
Diopsys offers NOVA Vision Testing System, VEP, and ERG.
Diopsys has 1 investor. Key investors include LumiThera.